Nicotinic acetylcholine (nACh) receptors are pentameric ligand-gated ion channels that mediate fast synaptic transmission. The α4β2 nACh receptor is highly expressed in the brain and exists in two functional stoichiometries: the (α4)(β2) and (α4)(β2) that differ by an ACh-binding site at the α4-α4 interface of (α4)(β2) receptors. Methyllycaconitine (MLA) is an nACh receptor antagonist, and while potent at both α7 and α4β2 nACh receptors, it has a higher selectivity for the α7 nACh receptor. The anthranilate-succinimide ester side-chain is important for its activity and selectivity. Here we identify a simplified MLA analogue that contains only the A and E ring skeleton of MLA, AE succinimide, that binds close to the channel lumen to display insurmountable inhibition at α4β2 nACh receptors. Although inhibition by AE succinimide was found to be voltage-dependent indicating a possible pore channel blocker, substituted-cysteine accessibility experiments indicated it did not bind between 2'-16' region of the channel pore. Instead, we found that upon binding and in the presence of ACh, there is a conformational change to the channel membrane that was identified when the compound was assessed against (α4 V13'C)β2 nACh receptors. It was found that in the 3:2 stoichiometry the two adjacent α4 subunits containing 13' cysteine mutations formed a disulfide bond and occluded ion conductance. This was reversed by treatment with the reducing agent, dithiothreitol. Thus, AE succinimide has a different mechanism of inhibition to both MLA and other AE analogues, such as AE bicyclic alcohol, in that upon binding to an as yet unidentified site, AE succinimide in the presence of ACh induces a conformational change to the channel that generates a ligand-bound closed state.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.9b00525DOI Listing

Publication Analysis

Top Keywords

nach receptors
16
α4β2 nach
12
nach receptor
12
nicotinic acetylcholine
8
presence ach
8
conformational change
8
change channel
8
α4β2
7
nach
7
succinimide
5

Similar Publications

Article Synopsis
  • A meta-analysis was conducted to compare the effectiveness of sacubitril-valsartan (S/V) versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in preventing recurrent atrial fibrillation (AF) after catheter ablation.
  • The study included four clinical trials with 642 total patients, showing that the S/V group had a significantly lower rate of persistent AF (RR: 0.54) and a reduction in left atrial volume compared to the ACEI/ARB group.
  • While S/V appears more effective in reducing AF recurrence, the left ventricular ejection fraction did not differ significantly between the two treatments, highlighting the need for
View Article and Find Full Text PDF

[Hand-foot syndrome after taking fibroblast growth factor receptor 2 inhibitor].

Dermatologie (Heidelb)

October 2024

Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München, LMU München, Frauenlobstr. 9-11, 80337, München, Deutschland.

View Article and Find Full Text PDF

Objectives: Neurological disorders represent a significant global health challenge, necessitating the exploration of novel therapeutic agents. Apigenin, a natural flavonoid abundantly found in various plants, has garnered attention for its potential neuroprotective properties. In this study, we employed molecular docking simulations to investigate the interaction between apigenin and key molecular targets associated with neurological disorders.

View Article and Find Full Text PDF

Galantamine suppresses α-synuclein aggregation by inducing autophagy via the activation of α nicotinic acetylcholine receptors.

J Pharmacol Sci

October 2024

Pharmacology and Neurobiology Laboratory, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan. Electronic address:

Article Synopsis
  • Synucleinopathies like Parkinson's disease and dementia involve problems in the brain caused by a protein called α-synuclein.
  • Currently, there are no effective treatments for these disorders, but researchers found that a drug called galantamine might help by preventing harmful protein buildup.
  • Studies showed that galantamine could protect brain cells and stop the spread of α-synuclein in mice, which means it could be a promising new treatment option.
View Article and Find Full Text PDF

Rationale: Although the mesocorticolimbic dopamine (DA) system is the main neurochemical substrate that regulates the addictive and reinforcing effects of ethanol (EtOH), other neurotransmitter systems, such as the acetylcholine (Ach) system, modulate DAergic function in the nucleus accumbens (nAcc). Previously, we reported that intra-nAcc administration of the nicotinic Ach receptor agonist cytisine increased oral EtOH self-administration. GABAB receptors in the nAcc are expressed in DAergic terminals, inhibit the regulation of DA release into the nAcc, and could modulate the effects of cytisine on oral EtOH self-administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!